Amenorrhea represents one of the most clinically significant disruptions of female reproductive endocrinology, serving as an overt indicator of underlying physiological, anatomical, or neuroendocrine dysfunction. Far from being an isolated pathology, the cessation or failure of menses reflects complex interactions across the hypothalamic-pituitary-ovarian axis and systemic somatic health. Investigating this symptom requires a multifaceted clinical approach that bridges reproductive medicine, psychology, nutritional science, and molecular genetics.
Amenorrhea
1. Concise Definition
Amenorrhea is defined clinically as the complete absence or abnormal cessation of menstrual bleeding in an individual of reproductive age. It is categorized fundamentally into primary amenorrhea, marked by the failure to initiate menarche, and secondary amenorrhea, characterized by the cessation of previously established menses for a period exceeding three to six months. Rather than denoting a standalone disease entity, amenorrhea functions as a cardinal clinical manifestation that points to an extensive differential diagnosis spanning structural anomalies to systemic endocrinopathies.
In standard reproductive endocrinology, primary amenorrhea is identified when a female has not attained menarche by age 15 in the presence of normal secondary sexual characteristics, or by age 13 in the absence of secondary sexual characteristics such as thelarche. Secondary amenorrhea refers to the absence of menses for three consecutive cycles in a person with previously regular cycles, or for six consecutive months in a person with irregular menstrual patterns. Both variants necessitate a thorough diagnostic evaluation because prolonged hypoestrogenism or unaddressed endocrine disorders carry profound implications for skeletal density, cardiovascular integrity, and long-term fertility.
The scope of this condition also intersects with regular physiologic transitions, as amenorrhea represents a standard state prior to pubertal maturation, during pregnancy and lactation, and following natural menopause. When unprompted by these natural life phases, the symptom demands diagnostic triage to discern whether the root failure stems from an anatomical outflow tract obstruction, gonadal dysgenesis, pituitary insufficiency, or hypothalamic dysregulation.
2. Etymology & Linguistic Origin
The term amenorrhea is derived from classical Greek linguistic roots that systematically describe the biological event. It incorporates the negative prefix a- (ἀ-), meaning “without” or “lacking”; the morpheme men (μήν), which translates to “month” and denotes the monthly cadence of menstrual bleeding; and the verbal root rhoia (ῥοία), derived from rhein (ῥεῖν), meaning “to flow.” The Latinized medical combining form -rrhoea entered Neo-Latin medical discourse during the late eighteenth and early nineteenth centuries.
Historically, vernacular medical writings in the seventeenth century frequently referred to absent menses using colloquial phrases such as the “suppression of the courses” or “retention of the menses.” The adoption of the formal term “amenorrhoea” (with the British English diphthong oe) into modern clinical lexicons gained widespread traction through nineteenth-century medical treatises across Western Europe. This formalization reflected a concerted effort to shift obstetrical and gynecological terminology away from humoral language toward standardized Greco-Latin anatomical and physiological classifications.
3. Pronunciation & Grammatical Form
In standard medical English, amenorrhea is pronounced phonetically as /eɪˌmɛn.əˈriː.ə/ or /əˌmɛn.əˈriː.ə/. The primary stress falls upon the penultimate syllable (“-ree-“), with secondary stress positioned on the initial or second syllable depending on regional dialect. The standard American English spelling is amenorrhea, whereas British English and Commonwealth jurisdictions conventionally preserve the classical diphthong as amenorrhoea.
Grammatically, the word functions as an uncountable noun (e.g., “the patient presented with persistent secondary amenorrhea”). The derivative adjective is amenorrheic (or amenorrhoeic), utilized to describe individuals or states characterized by the absence of menses (e.g., “an amenorrheic athlete”). While rarely used in modern clinical practice, the verbal formulation “to amenorrhoeate” has appeared in historical literature, though contemporary practice favors phrasing such as “developing amenorrhea” or “becoming amenorrheic.”
4. Detailed Conceptual Explanation
To grasp the conceptual complexity of amenorrhea, one must understand the delicate orchestration of the hypothalamic-pituitary-gonadal axis. The initiation and ongoing regularity of the menstrual cycle rely on pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus of the hypothalamus. This pulsatility directs the anterior pituitary gland to synthesize and release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In response, the ovaries initiate follicular development, leading to the cyclic production of estradiol and progesterone, which sequentially proliferate and differentiate the endometrium. Menstruation represents the shedding of this specialized endometrial lining triggered by the withdrawal of steroidal support, provided that a patent female reproductive tract exists to allow the outflow of blood.
A disruption at any anatomical or physiological level along this cascade precipitates amenorrhea. Disruption of hypothalamic GnRH pulsatility results in hypogonadotropic hypogonadism, leaving the ovaries quiescent due to absent pituitary stimulation. Conversely, primary ovarian insufficiency (hypergonadotropic hypogonadism) disrupts ovarian follicular reserve or cellular response mechanisms, leading to depleted sex steroid synthesis despite compensatory elevations in FSH and LH. Outflow tract abnormalities constitute a distinct category wherein hormonal signaling operates normally, but structural barriers—such as an imperforate hymen, transverse vaginal septum, or acquired intrauterine adhesions—physically prevent menstrual egress.
The clinical scope of amenorrhea extends far beyond reproductive capability. Circulating estradiol plays a decisive role in regulating bone mineral metabolism by suppressing osteoclastic bone resorption. Chronic hypoestrogenic amenorrhea directly leads to rapid bone mass deterioration, conferring an elevated risk for osteopenia and premature osteoporosis. Furthermore, estrogen maintains vascular endothelial nitric oxide synthesis and healthy lipid profiles; prolonged deficiency alters vascular tone, accelerates dyslipidemia, and elevates long-term cardiovascular risks.
Conversely, states of amenorrhea characterized by anovulation with persistent or unopposed estrogen exposure—such as classical polycystic ovary syndrome (PCOS)—present an opposing pathophysiological concern. In these scenarios, the absence of cyclic progesterone synthesis leaves the endometrium under constant mitogenic stimulation from estrogen. This environment elevates the risk for endometrial hyperplasia and progression toward well-differentiated endometrioid adenocarcinoma, demonstrating that amenorrhea encompasses both hypoestrogenic and hyperestrogenic pathological states.
5. Historical Development
Descriptions of absent menstruation can be traced through ancient medical corpora, including the writings of Hippocrates (circa 460–370 BCE) and Soranus of Ephesus (first to second century CE). In classical Greco-Roman medicine, the suppression of menses was interpreted through humoral theory, wherein menstrual blood was viewed as a natural purging mechanism for bodily plethoras and excess humors. The retention of menses was thought to cause systemic toxicity, wandering of the womb (hysteria), or severe pulmonary congestion, prompting therapeutic interventions designed to encourage blood flow via venesection, herbal emmenagogues, and thermal baths.
During the Renaissance and Enlightenment periods, anatomical dissections advanced the understanding of human pelvic organs, yet the functional hormonal mechanics of menstruation remained enigmatic. Menstruation was frequently tied to lunar cycles or general systemic vitality. It was not until the mid-to-late nineteenth century that researchers discovered that menstruation depended on ovarian function rather than being an autonomous uterine phenomenon. The pioneering experiments of Emil Knauer in 1896, demonstrating that ovarian transplantation in animals prevented uterine atrophy following bilateral oophorectomy, established that chemical messengers transported through the bloodstream dictated menstrual function.
The twentieth century marked an explosion in molecular and neuroendocrinological discovery. In the 1930s and 1940s, researchers successfully isolated and synthesized estrogen and progesterone. The landmark identification of GnRH by Roger Guillemin and Andrew Schally in the late 1960s—work recognized with the Nobel Prize in Physiology or Medicine in 1977—unlocked the understanding of central neuroendocrine control over the reproductive system. During this same era, Joseph Asherman documented intrauterine adhesions as a mechanical etiology of secondary amenorrhea in 1948 (Asherman’s syndrome), and cytogenetic advances clarified the 45,X karyotype underlying Turner syndrome, cementing the contemporary structural and genetic taxonomy of amenorrhea.
6. Theoretical Foundations
Modern reproductive physiology frames amenorrhea through several established biological models. Central to this theoretical architecture is the “Critical Energy Availability Theory,” which provides the physiological foundation for Functional Hypothalamic Amenorrhea (FHA). Formulated largely through the foundational work of Anne Loucks and colleagues, this model posits that the human neuroendocrine reproductive axis serves as an evolutionary luxury. When nutritional intake minus exercise energy expenditure yields an energy availability threshold below approximately 30 kilocalories per kilogram of fat-free mass per day, the body initiates an adaptive survival triage.
In this energy-conserving state, the central nervous system suppresses energetically costly processes, such as reproduction and linear growth, to preserve cellular life, thermoregulation, and locomotion. At the molecular level, this metabolic suppression is mediated by altered signaling molecules, including depressed leptin and insulin-like growth factor 1 (IGF-1), elevated ghrelin, and activation of the hypothalamic-pituitary-adrenal (HPA) axis with heightened cortisol secretion. These metabolic and stress signals converge upon kisspeptin-expressing neurons within the infundibular and rostral periventricular nuclei, downregulating kisspeptin release, which blunts pulsatile GnRH discharge and drives secondary amenorrhea.
A parallel theoretical framework centers on the “Two-Cell, Two-Gonadotropin Theory” of ovarian steroidogenesis. This model describes the obligatory cooperative interaction between thecal and granulosa cells in the ovarian follicle. LH stimulates thecal cells to convert cholesterol into androgens (androstenedione and testosterone), which subsequently diffuse across the basement membrane to granulosa cells. There, FSH activates the cytochrome P450 aromatase enzyme to convert androgens into estrone and estradiol. Disruptions in this coordinated system, whether through hyperandrogenic stromal expansion in polycystic ovary syndrome or premature follicular apoptosis in primary ovarian insufficiency, arrest follicular maturation and prevent the preovulatory estradiol surge required for ovulation and cyclic menstruation.
7. Key Components, Types & Dimensions
The classification of amenorrhea is traditionally arranged into distinct anatomical and functional categories that guide systematic evaluation:
- Primary Amenorrhea: The clinical failure to achieve menarche by age 15 in the presence of normal secondary sexual development, or by age 13 in the absence of secondary sexual characteristics. Common etiologies include:
- Gonadal Dysgenesis: Turner syndrome (45,X karyotype or structural variants) and pure gonadal dysgenesis (46,XX or 46,XY Swyer syndrome), representing the most frequent cause of primary hypergonadotropic hypogonadism.
- Müllerian Agenesis (Mayer-Rokitansky-Küster-Hauser Syndrome): Congenital absence or hypoplasia of the uterus, cervix, and upper two-thirds of the vagina in an individual with a normal 46,XX karyotype and functioning ovaries.
- Androgen Insensitivity Syndrome: A 46,XY disorder of sex development characterized by cellular insensitivity to androgens, leading to female external phenotypical development, intra-abdominal testes, absent internal female Müllerian structures, and primary amenorrhea.
- Anatomical Outflow Tract Obstructions: Isolated imperforate hymen or transverse vaginal septum causing cryptomenorrhea (hidden menses), wherein menstrual blood is produced but obstructed from exit.
- Congenital Hypogonadotropic Hypogonadism: Isolated GnRH deficiency, such as Kallmann syndrome, which manifests alongside anosmia or hyposmia.
- Secondary Amenorrhea: The absence of menses for three months in women with previously regular cycles, or six months in those with irregular cycles. Common subtypes include:
- Functional Hypothalamic Amenorrhea (FHA): Anovulation driven by psychological stress, excessive physical exercise, eating disorders, or significant weight loss without organic anatomical lesions.
- Hyperprolactinemia: Elevated circulating prolactin driven by pituitary prolactinomas, pharmacological agents (e.g., antipsychotics, antiemetics), or primary hypothyroidism, which directly dampens GnRH pulsatility.
- Polycystic Ovary Syndrome (PCOS): The most common endocrine cause of secondary amenorrhea, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology.
- Primary Ovarian Insufficiency (POI): Premature depletion or dysfunction of ovarian follicles prior to age 40, characterized by elevated gonadotropins and low estradiol.
- Uterine Synechiae (Asherman’s Syndrome): Obliteration of the endometrial cavity by intrauterine scar tissue, typically following curettage procedures complicated by infection or trauma.
8. Examples & Illustrative Cases
To ground these classifications in clinical reality, consider the following real-world clinical presentations:
Case 1: Primary Amenorrhea via Anatomical Obstruction
A 14-year-old girl presents to the adolescent clinic complaining of severe, cyclic monthly lower abdominal cramping that has escalated over the past four months, without any visible vaginal bleeding. Physical examination reveals normal breast development and axillary/pubic hair distribution (Tanner Stage IV). Pelvic examination reveals a tense, bluish, bulging membrane at the vaginal introitus. Pelvic ultrasound confirms a large hematocolpos and hematometra (retention of menstrual blood within the vaginal canal and uterine cavity) secondary to an imperforate hymen. A minor surgical hymenotomy yields immediate drainage of trapped menstrual fluid, resolving the pain and establishing normal anatomical menstrual flow.
Case 2: Functional Hypothalamic Amenorrhea in an Elite Athlete
A 19-year-old collegiate middle-distance runner reports that her menses, which began at age 12 and were historically predictable, have been entirely absent for the past eight months. During this interval, she increased her training mileage from 40 to 75 miles per week and restricted her dietary intake to reduce body weight. Her body mass index (BMI) is 17.8 kg/m². Serum testing reveals suppressed LH (1.1 mIU/mL), low-normal FSH (3.2 mIU/mL), and profoundly low estradiol (<20 pg/mL), with normal prolactin and thyroid-stimulating hormone levels. Dual-energy X-ray absorptiometry (DEXA) demonstrates a lumbar spine Z-score of -2.1, indicating low bone mass. This patient meets the diagnostic parameters for functional hypothalamic amenorrhea secondary to low energy availability, a core feature of the Relative Energy Deficiency in Sport (REDs) syndrome.
9. Measurement & Assessment
The diagnostic evaluation of amenorrhea follows an algorithmic sequence designed to isolate the level of physiological disruption while excluding physiological causes such as pregnancy. The primary step in assessing any patient presenting with amenorrhea is a sensitive urine or serum human chorionic gonadotropin (beta-hCG) assay to evaluate for gestation, regardless of stated sexual history.
Once pregnancy is ruled out, initial biochemical profiling includes:
- Serum Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH): Elevating FSH levels into postmenopausal ranges (>25–30 mIU/mL) confirms hypergonadotropic hypogonadism (primary ovarian insufficiency or gonadal dysgenesis). Conversely, low or inappropriately normal gonadotropins point to central hypothalamic or pituitary failure (hypogonadotropic hypogonadism).
- Serum Prolactin: Measured to screen for prolactin-secreting pituitary adenomas or medication-induced dopamine antagonism.
- Thyroid-Stimulating Hormone (TSH): Screens for clinical or subclinical thyroid dysfunction, as hypothyroidism elevates thyrotropin-releasing hormone (TRH), which can stimulate prolactin and disrupt ovulation.
- Total and Free Testosterone / DHEA-S: Indicated when clinical signs of androgen excess (hirsutism, severe acne, androgenic alopecia) suggest PCOS or an androgen-secreting neoplasm.
The Progestin Challenge Test (historically referred to as the progesterone withdrawal challenge) involves administering oral medroxyprogesterone acetate (10 mg daily for 10 days) or micronized progesterone. If the patient experiences withdrawal bleeding within 2 to 7 days following completion of the course, it demonstrates that the patient has an intact outflow tract and an endometrium that has been sufficiently primed by endogenous estrogen, confirming anovulation with intact estrogen production (most commonly PCOS). Failure to experience withdrawal bleeding indicates either an outflow tract defect (e.g., Asherman’s syndrome) or profound hypoestrogenism, requiring an Estrogen-Progestin Challenge to confirm endometrial responsiveness.
Imaging studies feature prominently in the diagnostic pathway. Transvaginal or transabdominal ultrasonography evaluates the presence, configuration, and endometrial thickness of the uterus, while checking for polycystic ovarian morphology or ovarian masses. When congenital primary amenorrhea is investigated, magnetic resonance imaging (MRI) of the pelvis provides high-resolution visualization of internal Müllerian anatomy. If hypogonadotropic hypogonadism is accompanied by neurological symptoms, elevated prolactin, or unexplained central suppression, MRI of the sella turcica is essential to rule out prolactinomas, craniopharyngiomas, or empty sella syndrome.
10. Applications & Practical Significance
The clinical and operational significance of amenorrhea spans across several primary disciplines, demanding tailored interdisciplinary management protocols:
In sports medicine and athletic training, amenorrhea serves as a vital clinical biomarker for the Female Athlete Triad and Relative Energy Deficiency in Sport (REDs). Recognizing amenorrhea in female athletes allows coaches, nutritionists, and sports physicians to intervene before irreversible bone mineral density loss and recurrent stress fractures occur. Nutritional rehabilitation and calibrated reductions in training load are prioritized over simple hormonal suppression via combined oral contraceptives, as oral estrogen can mask underlying energetic deficits while providing suboptimal skeletal protection relative to physiological recovery.
In adolescent medicine and psychiatry, the emergence of amenorrhea is frequently the first physical clue prompting assessment for eating disorders, such as anorexia nervosa or bulimia nervosa. Because patients may conceal disordered eating or excessive exercise patterns, menstrual cessation provides an objective marker of systemic energy deficiency. Multidisciplinary treatment models integrating cognitive-behavioral therapy, medical monitoring, and dietary refeeding are essential to restore neuroendocrine function.
In fertility management and reproductive endocrinology, treating amenorrhea depends directly on addressing the underlying etiology. For patients with PCOS seeking pregnancy, first-line medical therapy involves ovulation induction using aromatase inhibitors (e.g., letrozole) or selective estrogen receptor modulators (e.g., clomiphene citrate). For patients with hypogonadotropic hypogonadism, exogenous gonadotropin injections (FSH and LH) or pulsatile GnRH therapy are required to drive follicular growth. Women with permanent ovarian failure or gonadal dysgenesis must rely on assisted reproductive technology involving donor oocytes combined with exogenous hormone support.
11. Research & Empirical Evidence
Contemporary clinical research into amenorrhea has unraveled the molecular networks that govern central hypothalamic pulsatility. The discovery of the kisspeptin-neurokinin B-dynorphin (KNDy) neuronal network within the arcuate nucleus has redefined the neurobiological model of GnRH control. Studies conducted by Navarro et al. and Seminara et al. revealed that loss-of-function mutations in kisspeptin receptor genes (KISS1R) lead to idiopathic hypogonadotropic hypogonadism and absent puberty, establishing kisspeptin as a core regulator of reproductive function.
Empirical investigations led by Gordon et al. and published in consensus guidelines by the Endocrine Society have clarified the bone microarchitecture changes seen in functional hypothalamic amenorrhea. Longitudinal high-resolution peripheral quantitative computed tomography (HR-pQCT) demonstrates that hypoestrogenic amenorrhea causes significant trabecular and cortical microarchitectural deterioration within 12 to 24 months of onset. Clinical trials demonstrate that while oral contraceptive pills restore regular withdrawal bleeding, they fail to substantially improve bone mineral density because the first-pass hepatic metabolism of oral ethinyl estradiol suppresses systemic IGF-1 production. In contrast, transdermal 17-beta estradiol combined with cyclic oral micronized progesterone avoids hepatic IGF-1 suppression and significantly enhances bone accrual in amenorrheic young women.
In the field of reproductive genetics, high-throughput whole-exome sequencing has deepened our understanding of primary ovarian insufficiency. Research has identified diverse monogenic contributors beyond fragile X premutations (FMR1), highlighting mutations in meiotic recombination genes (e.g., MCM8, MCM9) and folliculogenesis transcription factors (e.g., FOXL2, FIGLA). These genetic insights are reshaping how clinicians approach reproductive lifespan prognosis, family counseling, and early fertility preservation strategies.
12. Cultural & Cross-Cultural Considerations
Cultural interpretations of amenorrhea vary substantially across different global communities, shaping healthcare-seeking behaviors and diagnostic timing. In cultures where menstrual blood is considered an index of physical purification and fertility, the cessation of menses is frequently viewed with significant distress, carrying deep social stigma regarding womanhood, marriageability, and social status. In contrast, in some high-performance subcultures—such as competitive long-distance running, professional ballet, or fitness modeling—amenorrhea is often mistakenly normalized as a routine byproduct of rigorous physical conditioning, leading athletes to delay medical assessment.
In certain under-resourced regions, socio-cultural factors such as dietary taboos, chronic nutritional scarcity, and early physical labor contribute to delayed menarche and underdiagnosed secondary amenorrhea. Religious practices and communal customs regarding menstrual seclusion can also complicate the clinical history; individuals may obscure amenorrhea to avoid social suspicion or isolation. Healthcare providers navigating diverse populations must approach menstrual health with cultural humility, exploring patients’ distinct conceptual models of bodily flow, blood retention, and reproductive vitality while dispelling misconceptions about the clinical implications of absent menses.
13. Criticisms, Debates & Limitations
A longstanding debate within clinical gynecology centers on the routine prescription of combined oral contraceptive pills (COCPs) for functional hypothalamic amenorrhea. Many clinicians historically used COCPs to provide a quick fix for the symptom by inducing artificial, cyclic withdrawal bleeding. Critics argue that this practice masks ongoing hypothalamic suppression, provides patients with a false sense of physiological recovery, and overlooks the root cause: chronic energy deficit and psychological stress. Furthermore, evidence shows that the synthetic estrogens in COCPs fail to optimize skeletal health to the same degree as genuine nutritional recovery or physiological transdermal hormone therapy.
Another ongoing nosological debate revolves around the diagnostic criteria for polycystic ovary syndrome, specifically the Rotterdam 2003 consensus versus narrower NIH criteria. Under the Rotterdam criteria, an individual can receive a diagnosis of PCOS on the basis of polycystic ovarian morphology on ultrasound combined with irregular cycles or amenorrhea, even in the complete absence of clinical or biochemical hyperandrogenism. Critics argue that this leads to overdiagnosis, pathologizing mild hypothalamic disturbances or normal post-menarchal transitions under the PCOS umbrella, which can alter treatment trajectories and induce unnecessary psychological distress.
14. Related Terms & Distinctions
Discerning amenorrhea from related clinical entities requires careful evaluation of cycle duration, flow volume, and anatomical features:
- Oligomenorrhea: Refers to abnormally infrequent menstrual periods where cycle intervals exceed 35 days, or where fewer than nine cycles occur annually. Amenorrhea represents the extreme end of this spectrum, marked by total cessation of bleeding for three to six months.
- Dysmenorrhea: Severe, painful cramping during menstruation. While dysmenorrhea concerns menstrual pain, amenorrhea denotes the complete absence of menstrual discharge; however, cryptomenorrhea (obstructed outflow) can manifest with severe cyclic pelvic pain that mimics dysmenorrhea without visible blood.
- Hypomenorrhea: Characterized by unusually light menstrual flow occurring at regular, normal cycle intervals. Unlike amenorrhea, cyclicity and endometrial shedding are fully preserved.
- Menopause: The permanent cessation of menstruation resulting from the natural, age-related exhaustion of ovarian follicular activity, clinically confirmed after 12 consecutive months of amenorrhea. When this occurs prior to age 40, it is classified pathologically as Primary Ovarian Insufficiency (POI) rather than physiological menopause.
- Cryptomenorrhea: Menstruation that occurs physiologically but is mechanically barred from exiting the external genitalia due to congenital tract obstructions such as an imperforate hymen or transverse vaginal septum.
15. Summary / Key Takeaways
Amenorrhea is an essential clinical indicator within reproductive medicine, signaling functional, anatomical, or endocrine alterations across the hypothalamic-pituitary-ovarian axis. Categorized into primary (failure to establish menarche) and secondary (cessation of established menses) forms, its presentation demands an immediate diagnostic search that prioritizes ruling out pregnancy before systematically interrogating endocrine, ovarian, and structural causes.
Understanding amenorrhea as an early systemic warning sign—rather than an isolated gynecological inconvenience—is fundamental to modern clinical practice. Whether signaling severe systemic energy deficits in athletes, hyperandrogenic metabolic shifts in PCOS, genetic variations in young adolescents, or impending bone density loss from prolonged hypoestrogenism, early identification and root-cause therapy safeguard patient bone health, cardiovascular wellbeing, and long-term reproductive vitality.
References
- American College of Obstetricians and Gynecologists. (2014). ACOG Committee Opinion No. 605: Primary amenorrhea. Obstetrics & Gynecology, 124(6), 1269–1272. https://doi.org/10.1097/01.AOG.0000459865.29497.63
- Gordon, C. M., Ackerman, K. E., Berga, S. L., Kaplan, J. R., Mastorakos, G., Misra, M., Murad, M. H., Santoro, N. F., & Warren, M. P. (2017). Functional hypothalamic amenorrhea: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 102(5), 1413–1439. https://doi.org/10.1210/jc.2017-00131
- Mountjoy, M., Sundgot-Borgen, J., Burke, L., Ackerman, K. E., Blauwet, C., Constantini, N., Lebrun, C., Lundy, B., Melin, A., Meyer, N., Sherman, R., Tenforde, A. S., Torstveit, M. K., & Budgett, R. (2018). International Olympic Committee (IOC) consensus statement on relative energy deficiency in sport (RED-S): 2018 update. British Journal of Sports Medicine, 52(11), 687–697. https://doi.org/10.1136/bjsports-2018-099508
- Practice Committee of the American Society for Reproductive Medicine. (2008). Current evaluation of amenorrhea. Fertility and Sterility, 90(5 Suppl), S219–S225. https://doi.org/10.1016/j.fertnstert.2008.08.038